{"id":"https://openalex.org/W147860503","doi":"https://doi.org/10.1161/circ.116.suppl_16.ii_549-a","title":"Abstract 2491: Neurohumoral Effects Of A New Oral Direct Renin Inhibitor In Stable Heart Failure: The Aliskiren Observation Of Heart Failure Treatment Study (ALOFT).","display_name":"Abstract 2491: Neurohumoral Effects Of A New Oral Direct Renin Inhibitor In Stable Heart Failure: The Aliskiren Observation Of Heart Failure Treatment Study (ALOFT).","publication_year":2007,"publication_date":"2007-10-16","ids":{"openalex":"https://openalex.org/W147860503","doi":"https://doi.org/10.1161/circ.116.suppl_16.ii_549-a","mag":"147860503"},"language":"en","primary_location":{"id":"doi:10.1161/circ.116.suppl_16.ii_549-a","doi":"https://doi.org/10.1161/circ.116.suppl_16.ii_549-a","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circ.116.suppl_16.ii_549-a","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042843111","display_name":"Bertram Pitt","orcid":"https://orcid.org/0000-0001-5880-275X","observed_orcids":["https://orcid.org/0000-0001-5880-275X","https://orcid.org/0000-0001-7703-0345"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bertram Pitt","raw_affiliation_strings":["Univ OF MICHIGAN, Ann Arbor, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ OF MICHIGAN, Ann Arbor, MI","institution_ids":["https://openalex.org/I27837315"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027213857","display_name":"John J.V. McMurray","orcid":"https://orcid.org/0000-0002-6317-3975","observed_orcids":["https://orcid.org/0000-0002-6317-3975"]},"institutions":[{"id":"https://openalex.org/I2801120601","display_name":"Western Infirmary","ror":"https://ror.org/02e22bh87","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800201399","https://openalex.org/I2801120601"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John J McMurray","raw_affiliation_strings":["Western Infirmary, Glasgow, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Western Infirmary, Glasgow, United Kingdom","institution_ids":["https://openalex.org/I2801120601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027518592","display_name":"Roberto Latini","orcid":"https://orcid.org/0000-0002-3729-4650","observed_orcids":["https://orcid.org/0000-0002-3729-4650"]},"institutions":[{"id":"https://openalex.org/I19630809","display_name":"Mario Negri Institute for Pharmacological Research","ror":"https://ror.org/05aspc753","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I19630809","https://openalex.org/I4210110338","https://openalex.org/I4210153126"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Roberto Latini","raw_affiliation_strings":["Istituto di Richerche Farmacologiche Mario Negri, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Istituto di Richerche Farmacologiche Mario Negri, Milan, Italy","institution_ids":["https://openalex.org/I19630809"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088186128","display_name":"Aldo Pietro Maggioni","orcid":"https://orcid.org/0000-0003-2764-6779","observed_orcids":["https://orcid.org/0000-0003-2764-6779"]},"institutions":[{"id":"https://openalex.org/I4210095959","display_name":"Associazione Nazionale Medici Cardiologi Ospedalieri","ror":"https://ror.org/00pyc4352","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I4210095959"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Aldo Maggioni","raw_affiliation_strings":["ANMCO Rsch Cntr, Florence, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ANMCO Rsch Cntr, Florence, Italy","institution_ids":["https://openalex.org/I4210095959"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054830306","display_name":"Scott David Solomon","orcid":"https://orcid.org/0000-0003-3698-9597","observed_orcids":["https://orcid.org/0000-0003-3698-9597"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott D Solomon","raw_affiliation_strings":["Brigham and Women\u2019s Hosp, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women\u2019s Hosp, Boston, MA","institution_ids":["https://openalex.org/I1283280774"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105024498","display_name":"Beverly A. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Beverly A Smith","raw_affiliation_strings":["Novartis Pharmaceuticals, East hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, East hanover, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087515399","display_name":"Christopher A. Bush","orcid":"https://orcid.org/0000-0001-5375-6459","observed_orcids":["https://orcid.org/0000-0001-5375-6459"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher A Bush","raw_affiliation_strings":["Novartis Pharmaceuticals, East Haover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, East Haover, NJ","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012641937","display_name":"MARGARET FORNEY PRESCOTT","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Margaret F Prescott","raw_affiliation_strings":["Novartis Pharmaceuticals, East Hanover, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals, East Hanover, NJ","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":11,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"116","issue":"suppl_16","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.6547999978065491,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":0.6547999978065491,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.31450000405311584,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11917","display_name":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","score":0.004699999932199717,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aliskiren","display_name":"aliskiren","score":1.0},{"id":"https://openalex.org/keywords/renin-inhibitors","display_name":"renin inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.9580000042915344},{"id":"https://openalex.org/keywords/renin-angiotensin-aldosterone-system","display_name":"renin-angiotensin-aldosterone system","score":0.953000009059906},{"id":"https://openalex.org/keywords/plasma-renin-activity","display_name":"plasma renin activity","score":0.9589999914169312},{"id":"https://openalex.org/keywords/brain-natriuretic-peptide","display_name":"brain natriuretic peptide","score":0.9750000238418579},{"id":"https://openalex.org/keywords/urinary-aldosterone-excretion","display_name":"urinary aldosterone excretion","score":0.8830000162124634},{"id":"https://openalex.org/keywords/beta-blockers","display_name":"beta-blockers","score":0.746999979019165},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.7310000061988831},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9940000176429749},{"id":"https://openalex.org/keywords/mineralocorticoid-receptor-antagonists","display_name":"mineralocorticoid receptor antagonists","score":0.9419999718666077}],"concepts":[{"id":"https://openalex.org/C2779838083","wikidata":"https://www.wikidata.org/wiki/Q414904","display_name":"Aliskiren","level":4,"score":0.9738463163375854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8808161020278931},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.7999300956726074},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6752967834472656},{"id":"https://openalex.org/C138976137","wikidata":"https://www.wikidata.org/wiki/Q7201790","display_name":"Plasma renin activity","level":4,"score":0.6200142502784729},{"id":"https://openalex.org/C2778525890","wikidata":"https://www.wikidata.org/wiki/Q184564","display_name":"Aldosterone","level":2,"score":0.6190840601921082},{"id":"https://openalex.org/C198710026","wikidata":"https://www.wikidata.org/wiki/Q898218","display_name":"Renin\u2013angiotensin system","level":3,"score":0.5330774784088135},{"id":"https://openalex.org/C2777425892","wikidata":"https://www.wikidata.org/wiki/Q409255","display_name":"Renin inhibitor","level":4,"score":0.5292792916297913},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5256073474884033},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.48077601194381714},{"id":"https://openalex.org/C2779611605","wikidata":"https://www.wikidata.org/wiki/Q288280","display_name":"ACE inhibitor","level":4,"score":0.43965667486190796},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4205157160758972},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36644160747528076},{"id":"https://openalex.org/C27016395","wikidata":"https://www.wikidata.org/wiki/Q128861","display_name":"Angiotensin-converting enzyme","level":3,"score":0.23190593719482422},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.2297767996788025},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1161/circ.116.suppl_16.ii_549-a","doi":"https://doi.org/10.1161/circ.116.suppl_16.ii_549-a","is_oa":false,"landing_page_url":"https://doi.org/10.1161/circ.116.suppl_16.ii_549-a","pdf_url":null,"source":{"id":"https://openalex.org/S116251202","display_name":"Circulation","issn_l":"0009-7322","issn":["0009-7322","1524-4539"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Circulation","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1994079702","https://openalex.org/W2006078326","https://openalex.org/W2056076534","https://openalex.org/W2126904599","https://openalex.org/W1994288384","https://openalex.org/W2093276210","https://openalex.org/W1016248440","https://openalex.org/W2131178128","https://openalex.org/W2281074424","https://openalex.org/W2020061449"],"abstract_inverted_index":{"Background:":[0],"Treatments":[1],"that":[2],"inhibit":[3],"the":[4,48,69,175],"renin-angiotensin-aldosterone":[5],"system":[6],"(RAAS)":[7],"are":[8,32,172],"of":[9,36,74,187],"established":[10],"benefit":[11],"in":[12,168,174,184,208,221,236],"heart":[13,89],"failure":[14,90],"(HF).":[15],"These":[16],"include":[17],"ACE-inhibitor,":[18],"angiotensin":[19],"receptor":[20],"blockers":[21,30],"(ARB)":[22],"and":[23,108,115,164,198,203,211,228,231],"aldosterone":[24,200],"antagonists":[25],"(AA).":[26],"In":[27,39],"addition,":[28],"beta":[29,226],"(BB)":[31],"also":[33],"effective":[34],"inhibitors":[35],"renin":[37,52,194],"secretion.":[38],"this":[40],"first":[41],"placebo-controlled":[42],"study,":[43],"we":[44],"have":[45],"investigated":[46],"whether":[47],"new":[49],"orally-active":[50],"direct":[51],"inhibitor,":[53],"aliskiren,":[54],"has":[55,229],"additional":[56,230],"neurohumoral":[57,234],"actions":[58],"when":[59],"added":[60,137],"to":[61,125,138,204],"these":[62],"proven":[63],"therapies.":[64],"Methods:":[65],"Inclusion":[66],"criteria":[67],"for":[68],"AL":[70],"iskiren":[71],"O":[72],"bservation":[73],"Heart":[75],"F":[76],"ailure":[77],"T":[78],"reatment":[79],"study":[80],"(ALOFT)":[81],"were:":[82],"age":[83,148],"18":[84],"years":[85],"or":[86,97,113,119,132],"older,":[87],"stable":[88],"with":[91,110,130,214,224,241],"NYHA":[92],"functional":[93],"class":[94],"II\u2013IV,":[95],"prior":[96],"current":[98],"hypertension,":[99],"plasma":[100,193],"B-type":[101],"natriuretic":[102],"peptide":[103],"(BNP)":[104],"concentration":[105],">100":[106],"pg/mL":[107],"treatment":[109,129],"an":[111,185,215],"ACE-I":[112],"ARB":[114],"BB,":[116],"unless":[117],"contraindicated":[118],"not":[120,212],"tolerated.":[121],"Patients":[122],"were":[123,154],"randomized":[124],"3":[126],"months":[127],"double-blind":[128],"placebo":[131],"aliskiren":[133],"(150":[134],"mg":[135],"qd),":[136],"standard":[139],"therapy.":[140],"Results:":[141],"Overall,":[142],"302":[143],"patients":[144,209,222,237],"(78%":[145],"male,":[146],"mean":[147,151],"68":[149],"years,":[150],"LVEF":[152],"31%)":[153],"randomized.":[155],"Baseline":[156],"treatment:":[157],"84%":[158],"ACE-I,":[159],"15%":[160],"ARB,":[161],"94%":[162],"BB":[163],"33%":[165],"AA.":[166,216],"Change":[167],"neurohormones":[169],"versus":[170],"baseline":[171],"shown":[173],"table":[176],"(expressed":[177],"as":[178],"%":[179],"change":[180],"using":[181],"geometric":[182],"means":[183],"analysis":[186],"covariance":[188],"model).":[189],"Aliskiren":[190,218],"significantly":[191],"suppressed":[192],"activity":[195],"(PRA),":[196],"BNP":[197],"urinary":[199],"excretion":[201],"overall":[202],"a":[205,225],"similar":[206],"extent":[207],"treated":[210,213,223,240],"Conclusions:":[217],"suppresses":[219],"PRA":[220],"blocker":[227],"potentially":[232],"beneficial":[233],"effects":[235],"already":[238],"comprehensively":[239],"neuroendocrine":[242],"antagonists.":[243]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2016-06-24T00:00:00"}